Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 5, 2006, Pages 1300-1306

  Chua, Daniel T T ^a   Ma, Jun ^b   Sham, Jonathan S T ^a   Mai, Hai Qiang ^b   Choy, Damon T K ^a   Hong, Ming Huang ^b   Lu, Tai Xiang ^b   Au, Gordon K H ^a   Min, Hua Qing ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Early stage; Induction chemotherapy; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

CARCINOGENS; CHEMOTHERAPY; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

INDUCTION CHEMOTHERAPY; METASTASIS FREE RATES; NASOPHARYNGEAL CARCINOMA;

ONCOLOGY;

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; ADULT; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NASOPHARYNX TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; REMISSION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; REMISSION INDUCTION; SURVIVAL RATE;

EID: 33748579563     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.02.016     Document Type: Article

References (20)

1. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer. Phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
2. Lin J.C., Jan J.S., Hsu C.Y., et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma. Positive effect on overall and progression-free survival. J Clin Oncol 21 (2003) 631-637
3. Chan A.T., Leung S.F., Ngan R.K., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97 (2005) 536-539
4. Wee J., Tan E.H., Tai B.C., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (2005) 6730-6738
5. International Nasopharynx Cancer Study Group. VUMCA I trial: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35 (1996) 463-469
6. Chua D.T.T., Sham J.S.T., Choy D., et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 83 (1998) 2270-2283
7. Ma J., Mai H., Hong M., et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19 (2001) 1350-1357
8. Hareyama M., Sakata K., Shirato H., et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94 (2002) 2217-2223
9. Baujat B., Amand C., Eschwege F., et al. Chemotherapy + radiotherapy versus radiotherapy alone in nasopharynx carcinoma. Preliminary results of a meta-analysis based on individual patient data. Int J Radiat Oncol Biol Phys 60 (2004) S191-S192
10. Chua D.T., Ma J., Sham J.S., et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma. A pooled data analysis of two phase III trials. J Clin Oncol 23 (2005) 1118-1124
11. American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. (1997), JB Lippincott, Philadelphia
12. Chua D.T., Sham J.S., Wei W.I., et al. The predictive value of the 1997 American Joint Committee on Cancer Stage Classification in determining failure patterns in nasopharyngeal carcinoma. Cancer 92 (2001) 2845-2855
13. Chan A.T., Teo P.M., Leung T.W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 (1995) 569-577
14. Lee A.W., Sze W.M., Au J.S., et al. Treatment results for nasopharyngeal carcinoma in the modern era. The Hong Kong experience. Int J Radiat Oncol Biol Phys 61 (2005) 1107-1116
15. Lee A.W., Poon Y.F., Foo W., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985. Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23 (1992) 261-270
16. Chua D.T., Sham J.S., Kwong D., et al. Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma. Cancer 98 (2003) 74-80
17. Leung T.W., Tung S.Y., Sze W.K., et al. Treatment results of 1070 patients with nasopharyngeal carcinoma. An analysis of survival and failure patterns. Head Neck 27 (2005) 555-565
18. Lee A.W., Lau W.H., Tung S.Y., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma. NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (2005) 6966-6975
19. Cheng S.H., Tsai S.Y., Yen K.L., et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 18 (2000) 2040-2045
20. Leung S.F., Chan A.T.C., Zee B., et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98 (2003) 288-291